{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:55:18Z","timestamp":1790117718830,"version":"4.0.1"},"reference-count":59,"publisher":"Society of Nuclear Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2024,9,9]]},"published-print":{"date-parts":[[2024,11]]},"DOI":"10.2967\/jnumed.124.268363","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T19:10:27Z","timestamp":1727982627000},"page":"1666-1671","source":"Crossref","is-referenced-by-count":16,"title":["Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy"],"prefix":"10.2967","volume":"65","author":[{"given":"Jeremie","family":"Calais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse Tuba","family":"Kendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash Rezazadeh","family":"Kalebasty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Tutrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"2025060410401059000_65.11.1666.1","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S360444"},{"key":"2025060410401059000_65.11.1666.2","unstructured":"Pluvicto (lutetium Lu-177 vipivotide tetraxetan) injection, for intravenous use. Prescribing information. Novartis; 2022."},{"key":"2025060410401059000_65.11.1666.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2025060410401059000_65.11.1666.4","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00720-2"},{"key":"2025060410401059000_65.11.1666.5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s11523-022-00925-7","article-title":"Addressing challenges and controversies in the management of prostate cancer with multidisciplinary teams","volume":"17","author":"Shore","year":"2022","journal-title":"Target Oncol."},{"key":"2025060410401059000_65.11.1666.6","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S117945"},{"key":"2025060410401059000_65.11.1666.7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.eururo.2023.12.004","article-title":"Safety analyses of the phase 3 VISION trial of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"85","author":"Chi","year":"2024","journal-title":"Eur Urol."},{"key":"2025060410401059000_65.11.1666.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2025060410401059000_65.11.1666.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262543"},{"key":"2025060410401059000_65.11.1666.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06255-8"},{"key":"2025060410401059000_65.11.1666.11","doi-asserted-by":"crossref","first-page":"102748","DOI":"10.1016\/j.ctrv.2024.102748","article-title":"Salivary toxicity from PSMA-targeted radiopharmaceuticals: what we have learned and where we are going","volume":"127","author":"Muniz","year":"2024","journal-title":"Cancer Treat Rev."},{"key":"2025060410401059000_65.11.1666.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264946"},{"key":"2025060410401059000_65.11.1666.13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12894-019-0527-8","article-title":"Prevalence of fatigue and impact on quality of life in castration-resistant prostate cancer patients: the VITAL study","volume":"19","author":"Rodr\u00edguez Antol\u00edn","year":"2019","journal-title":"BMC Urol."},{"key":"2025060410401059000_65.11.1666.14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaoncol.2016.6914","article-title":"Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue a meta-analysis","volume":"3","author":"Mustian","year":"2017","journal-title":"JAMA Oncol."},{"key":"2025060410401059000_65.11.1666.15","first-page":"1","article-title":"Anemia in men with advanced prostate cancer: incidence, etiology, and treatment","volume":"6","author":"Nalesnik","year":"2004","journal-title":"Rev Urol."},{"key":"2025060410401059000_65.11.1666.16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn250"},{"key":"2025060410401059000_65.11.1666.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.171397"},{"key":"2025060410401059000_65.11.1666.18","first-page":"539","article-title":"Practical guidance on [177Lu]Lu-PSMA-617 treatment, including radiation safety, adverse event monitoring, and patient counseling","volume":"27","author":"Spitz","year":"2023","journal-title":"Clin J Oncol Nurs."},{"key":"2025060410401059000_65.11.1666.19","doi-asserted-by":"crossref","first-page":"e17028","DOI":"10.1200\/JCO.2024.42.16_suppl.e17028","article-title":"Xerostomia and ocular dryness as predictors of PSA response to Lu177-PSMA-617 in metastatic castration resistant prostate cancer [abstract]","volume":"42","author":"Hassoun","year":"2024","journal-title":"J Clin Oncol."},{"key":"2025060410401059000_65.11.1666.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265952"},{"key":"2025060410401059000_65.11.1666.21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1200\/JCO.2022.40.6_suppl.037","article-title":"Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I\/II trial [abstract]","volume":"40","author":"Nauseef","year":"2022","journal-title":"J Clin Oncol."},{"key":"2025060410401059000_65.11.1666.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4135-8"},{"key":"2025060410401059000_65.11.1666.23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13550-021-00805-7","article-title":"Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"11","author":"Groener","year":"2021","journal-title":"EJNMMI Res."},{"key":"2025060410401059000_65.11.1666.24","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/bju.15542","article-title":"Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer","volume":"129","author":"Kreis","year":"2022","journal-title":"BJU Int."},{"key":"2025060410401059000_65.11.1666.25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11523-023-01016-x","article-title":"Hematological toxicity of PARP inhibitors in metastatic prostate cancer patients with mutations of BRCA or HRR genes: a systematic review and safety meta-analysis","volume":"19","author":"Maiorano","year":"2024","journal-title":"Target Oncol."},{"key":"2025060410401059000_65.11.1666.26","doi-asserted-by":"crossref","first-page":"e17057","DOI":"10.1200\/JCO.2023.41.16_suppl.e17057","article-title":"Tolerability of lutetium-177\u2013PSMA-617 in men with prostate cancer and baseline cytopenia [abstract]","volume":"41","author":"Abdelrazek","year":"2023","journal-title":"J Clin Oncol."},{"key":"2025060410401059000_65.11.1666.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2015.09.011"},{"key":"2025060410401059000_65.11.1666.28","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.1200\/JCO.2024.42.16_suppl.5075","article-title":"Hematologic toxicity in 177lu-PSMA-617 treatment for mCRPC: unraveling the impact of PSMA PET bone tumor volume (PSMA-bTTV) [abstract]","volume":"42","author":"Ghodsi","year":"2024","journal-title":"J Clin Oncol."},{"key":"2025060410401059000_65.11.1666.29","first-page":"241590","article-title":"Effect of bone marrow disease on hematologic toxicity and PSA response to 177Lu-PSMA-617 therapy [abstract]","volume":"65","author":"Losee","year":"2024","journal-title":"J Nucl Med."},{"key":"2025060410401059000_65.11.1666.30","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2020.05.004","article-title":"Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement: a multicenter retrospective study","volume":"78","author":"Gafita","year":"2020","journal-title":"Eur Urol."},{"key":"2025060410401059000_65.11.1666.31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2025060410401059000_65.11.1666.32","first-page":"e27266","article-title":"Potential ophthalmological side effects induced by anti-neoplastic regimens for the treatment of genitourinary cancers: a review","volume":"14","author":"Sakellakis","year":"2022","journal-title":"Cureus."},{"key":"2025060410401059000_65.11.1666.33","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.prro.2024.04.001","article-title":"Management of dry eye toxicity after treatment with 177Lu-PSMA-617 radioligand therapy","volume":"14","author":"Pepin","year":"2024","journal-title":"Pract Radiat Oncol."},{"key":"2025060410401059000_65.11.1666.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.006"},{"key":"2025060410401059000_65.11.1666.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02799.x"},{"key":"2025060410401059000_65.11.1666.36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40271-018-0349-x","article-title":"Symptoms and impacts in metastatic castration-resistant prostate cancer: qualitative findings from patient and physician interviews","volume":"12","author":"Holmstrom","year":"2019","journal-title":"Patient."},{"key":"2025060410401059000_65.11.1666.37","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s11255-017-1660-5","article-title":"Are we underestimating the rates of incontinence after prostate cancer treatment? Results from NHANES","volume":"49","author":"Daugherty","year":"2017","journal-title":"Int Urol Nephrol."},{"key":"2025060410401059000_65.11.1666.38","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/pcan.2016.62","article-title":"Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials","volume":"20","author":"Saad","year":"2017","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"2025060410401059000_65.11.1666.39","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1002\/cncr.32414","article-title":"Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database","volume":"125","author":"Tablazon","year":"2019","journal-title":"Cancer."},{"key":"2025060410401059000_65.11.1666.40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0815"},{"key":"2025060410401059000_65.11.1666.41","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00199-0"},{"key":"2025060410401059000_65.11.1666.42","first-page":"1834","article-title":"Neurologic complications of prostate cancer","volume":"65","author":"Benjamin","year":"2002","journal-title":"Am Fam Physician."},{"key":"2025060410401059000_65.11.1666.43","doi-asserted-by":"crossref","first-page":"102524","DOI":"10.1016\/j.ctrv.2023.102524","article-title":"Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer","volume":"115","author":"Calais","year":"2023","journal-title":"Cancer Treat Rev."},{"key":"2025060410401059000_65.11.1666.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.07.011"},{"key":"2025060410401059000_65.11.1666.45","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1088\/0952-4746\/36\/2\/269","article-title":"Evaluation of radiation safety in 177Lu-PSMA therapy and development of outpatient treatment protocol","volume":"36","author":"Demir","year":"2016","journal-title":"J Radiol Prot."},{"key":"2025060410401059000_65.11.1666.46","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.243238"},{"key":"2025060410401059000_65.11.1666.47","doi-asserted-by":"crossref","first-page":"1567\u20131569","DOI":"10.2967\/jnumed.123.265750","article-title":"Radiation safety considerations of household waste disposal after release of patients who have received [177Lu]Lu-PSMA-617","volume":"64","author":"Graves","year":"2023","journal-title":"J Nucl Med."},{"key":"2025060410401059000_65.11.1666.48","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.155390"},{"key":"2025060410401059000_65.11.1666.49","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1007\/s00259-022-05785-x","article-title":"Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre","volume":"49","author":"Herrmann","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060410401059000_65.11.1666.50","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1007\/s00259-023-06328-8","article-title":"Urinary excretion kinetics of [177Lu]Lu-PSMA-617","volume":"50","author":"Bakker","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060410401059000_65.11.1666.51","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.230607"},{"key":"2025060410401059000_65.11.1666.52","unstructured":"Lutathera 370 MBq\/mL solution for infusion. Summary of product characteristics. Novartis; 2017."},{"key":"2025060410401059000_65.11.1666.53","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.prro.2022.01.008","article-title":"Embracing the practical aspects of theranostics with prostate-specific membrane antigen-targeted lutetium-177","volume":"12","author":"Manogue","year":"2022","journal-title":"Pract Radiat Oncol."},{"key":"2025060410401059000_65.11.1666.54","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2010.000071"},{"key":"2025060410401059000_65.11.1666.55","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/JU.0000000000001375","article-title":"Advanced prostate cancer: AUA\/ASTRO\/SUO guideline","volume":"205","author":"Lowrance","year":"2020","journal-title":"J Urol."},{"key":"2025060410401059000_65.11.1666.56","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.semnuclmed.2021.11.003","article-title":"Radiation dosimetry in 177Lu-PSMA-617 therapy","volume":"52","author":"Jackson","year":"2022","journal-title":"Semin Nucl Med."},{"key":"2025060410401059000_65.11.1666.57","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264677"},{"key":"2025060410401059000_65.11.1666.58","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-070275"},{"key":"2025060410401059000_65.11.1666.59","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-030856"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.268363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T17:40:48Z","timestamp":1749058848000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.268363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":59,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,1]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.2967\/jnumed.124.268363"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.268363","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]}}}